###begin article-title 0
###xml 118 122 <span type="species:ncbi:10090">Mice</span>
A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: MD BJD. Performed the experiments: KJJ IJG TO ASC. Analyzed the data: KJJ IJG TO ASC ML MD. Contributed reagents/materials/analysis tools: KJJ IJG ASC. Wrote the paper: KJJ. Edited the revision of the paper: TO.
###end p 1
###begin p 2
###xml 513 516 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 748 751 748 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 825 833 825 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 843 849 <span type="species:ncbi:10090">murine</span>
The BCR-ABL tyrosine kinase is the defining feature of chronic myeloid leukemia (CML) and its kinase activity is required for induction of this disease. Current thinking holds that BCR-ABL forms a multi-protein complex that incorporates several substrates and adaptor proteins and is stabilized by multiple direct and indirect interactions. Signaling output from this highly redundant network leads to cellular transformation. Proteins known to be associated with BCR-ABL in this complex include: GRB2, c-CBL, p62DOK, and CRKL. These proteins in turn, link BCR-ABL to various signaling pathways indicated in cellular transformation. In this study we show that a triple mutant of BCR-ABL with mutations of the direct binding sites for GRB2, CBL, p62DOK and CRKL, is defective for transformation of primary hematopoietic cells in vitro and in a murine CML model, while it retains the capacity to induce IL-3 independence in 32D cells. Compared to BCR-ABL, the triple mutant's ability to activate the MAP kinase and PI3-kinase pathways is severely compromised, while STAT5 phosphorylation is maintained, suggesting that the former are crucial for the transformation of primary cells, but dispensable for transformation of factor dependent cell lines. Our data suggest that inhibition of BCR-ABL-induced leukemia by disrupting protein interactions could be possible, but would require blocking of multiple sites.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 146 149 146 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Lugo1">[1]</xref>
###xml 151 154 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Zhang1">[2]</xref>
###xml 192 195 192 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Lugo2">[3]</xref>
###xml 218 221 218 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-McLaughlin1">[4]</xref>
###xml 221 229 221 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 334 337 334 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Daley1">[5]</xref>
###xml 542 545 542 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Kelliher1">[6]</xref>
###xml 547 550 547 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Daley2">[7]</xref>
###xml 552 555 552 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Gishizky1">[8]</xref>
###xml 643 651 643 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 656 663 656 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 663 666 663 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Lugo1">[1]</xref>
###xml 668 671 668 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Zhang1">[2]</xref>
###xml 934 937 934 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 966 969 966 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler1">[9]</xref>
###xml 1115 1118 1115 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1135 1138 1135 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler1">[9]</xref>
###xml 1140 1144 1140 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Gotoh1">[10]</xref>
###xml 1146 1150 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Raitano1">[11]</xref>
###xml 1152 1156 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sawyers1">[12]</xref>
###xml 1275 1279 1275 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Pendergast1">[13]</xref>
###xml 1409 1412 1409 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler1">[9]</xref>
###xml 1414 1418 1414 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Gotoh1">[10]</xref>
###xml 1420 1424 1420 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Raitano1">[11]</xref>
###xml 1426 1430 1426 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sawyers1">[12]</xref>
###xml 175 178 <span type="species:ncbi:10116">Rat</span>
###xml 342 348 <span type="species:ncbi:10090">murine</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
The BCR-ABL tyrosine kinase is the molecular hallmark of chronic myeloid leukemia (CML) and its kinase activity is required for disease induction [1], [2]. BCR-ABL transforms Rat-1fibroblasts [3] and B-cell precursors [4]in vitro and confers interleukin-3 (IL-3) independent growth when expressed in IL-3 dependent myeloid cell lines [5]. In murine bone marrow transplantation/transduction experiments, BCR-ABL infected bone marrow transplanted into mice induces a myeloproliferative syndrome that is transplantable into secondary recipients [6], [7], [8]. Since the tyrosine kinase activity of BCR-ABL is essential for its oncogenic activity in vitro and in vivo[1], [2], much effort has been directed at determining which of its substrates are required for leukemogenesis. A number of BCR-ABL substrates have been identified, including BCR-ABL itself, CBL, CRKL, the p85 kDa regulatory subunit of phosphoinositide (PI) 3-kinase, p62DOK, RAS-GAP, paxillin, and SHC [9]. Co-immunoprecipitation experiments have shown that BCR-ABL forms stable complexes with several of these substrates including CRKL, SHC, CBL, p62DOK, and PI3-kinase [9], [10], [11], [12]. In addition, tyrosine phosphorylation of BCR-ABL at specific residues regulates the binding of proteins such as GRB2 [13]. As a result of these interactions many intracellular signaling pathways are activated, including the RAS, AKT and STAT pathways [9], [10], [11], [12]. In the complicated network of interactions that results, the role and relative importance of individual components has been difficult to establish.
###end p 4
###begin p 5
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Pendergast1">[13]</xref>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Puil1">[14]</xref>
###xml 667 671 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Goga1">[15]</xref>
###xml 824 828 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Million1">[16]</xref>
###xml 979 983 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Oda1">[17]</xref>
###xml 985 989 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-McWhirter1">[18]</xref>
###xml 991 995 991 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Ilaria1">[19]</xref>
###xml 1132 1136 1132 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Roumiantsev1">[20]</xref>
###xml 1209 1213 1209 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler2">[21]</xref>
###xml 1215 1219 1215 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat1">[22]</xref>
###xml 1227 1230 1227 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1230 1234 1230 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat2">[23]</xref>
###xml 1465 1472 1465 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCR-ABL</sup>
###xml 1472 1476 1472 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
###xml 1539 1546 1539 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCR-ABL</sup>
###xml 1558 1562 1558 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Dai1">[25]</xref>
###xml 733 739 <span type="species:ncbi:10090">murine</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
###xml 1523 1527 <span type="species:ncbi:10090">mice</span>
To determine the necessity of various proteins for BCR-ABL function, a common approach has been to identify a binding site for a specific protein on BCR-ABL, mutate the site and analyze the effect on BCR-ABL function. The ability of BCR-ABL constructs to transform IL-3 dependent hematopoietic cell lines to factor independent growth is a common tool used to assess BCR-ABL function. For example, tyrosine 177 of BCR-ABL is the binding site for the adaptor protein GRB2, which links BCR-ABL to the RAS pathway [13], [14]. BCR-ABL containing a mutation of this tyrosine to phenylalanine (Y177F) is still able to transform myeloid cell lines to IL-3 independent growth [15]. This Y177F mutant is also capable of inducing leukemia in a murine leukemia model, but the phenotype of the leukemia is lymphoid as opposed to myeloid [16]. Similar results were seen with a mutant lacking the SH2 domain. This BCR-ABL SH2 domain deletion mutant renders myeloid cells lines IL-3 independent [17], [18], [19], and induces a lymphoid leukemia or a CML-like disease in mice, but the disease latency is increased as compared to full length BCR-ABL [20]. The SH2 domain is reported to mediate direct binding of BCR-ABL to CBL [21], [22] and p62DOK[23]. In the C-terminus of BCR-ABL, a proline-rich region is a direct binding site for the adaptor protein CRKL. Deletion mutants in this region are capable of rendering myeloid cells growth factor independent in the background of p210BCR-ABL[24], and are also capable of inducing leukemia in mice in the p185BCR-ABL background [25].
###end p 5
###begin p 6
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
Although mutation of individual domains abolishes the direct interactions of a signaling protein with BCR-ABL, indirect interactions confound the ability to determine the role of a specific protein or pathway in BCR-ABL transformation. For example, direct binding of CRKL to BCR-ABL is abolished in the proline-rich deletion mutant, but CRKL interacts indirectly with BCR-ABL and is still tyrosine phosphorylated [24]. Therefore, to address the role of various signaling pathways simultaneously and to circumvent difficulties posed by the potential for indirect interactions, we created a mutant of BCR-ABL with a tyrosine to phenylalanine mutation at amino acid 177 (Y177F), an SH2 domain deletion (DeltaSH2) and a deletion of the C-terminal proline-rich region (DeltaPro). We assessed the ability of this triple mutant to transform myeloid cell lines and induce leukemia and analyzed its ability to interact with signaling proteins and activate downstream signaling pathways.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
The triple mutant of BCR-ABL is capable of inducing growth factor independence
###end title 8
###begin p 9
###xml 463 467 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Pendergast1">[13]</xref>
###xml 469 473 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Puil1">[14]</xref>
###xml 478 482 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler2">[21]</xref>
###xml 484 488 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat1">[22]</xref>
###xml 496 499 484 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 512 516 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat2">[23]</xref>
###xml 548 552 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
###xml 1255 1264 1235 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g001">Figure 1A</xref>
###xml 1356 1364 1336 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g001">Figure 1</xref>
###xml 1520 1529 1500 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007439.s001">Figure S1</xref>
###xml 2013 2022 1993 2002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g001">Figure 1B</xref>
32D cell lines were generated containing the pSRalpha vector, full length BCR-ABL without mutations, herein referred to as wild type BCR-ABL (WT), mutants of BCR-ABL containing a tyrosine to phenylalanine mutation at amino acid 177 (Y177F), a deletion of the SH2 domain (DeltaSH2), a deletion of a C-terminal proline-rich region (DeltaPro) and a triple mutant of BCR-ABL (triple) containing all three. These are reported to be direct binding sites for GRB2 (Y177)[13], [14], CBL[21], [22] and p62DOK (SH2 domain)[23], and CRKL (proline-rich region)[24]. Individual clones were isolated from soft agar cultures and evaluated for expression of BCR-ABL. Several clones expressing BCR-ABL at comparable levels were selected and analyzed for IL-3 dependence by cell proliferation and viability assays. All clones were maintained in the presence of IL-3 prior to assessment of factor independent growth. The parental 32D cells were unable to proliferate in the absence of IL-3, whereas wild type BCR-ABL, the Y177F, DeltaSH2, DeltaPro and the triple mutant BCR-ABL grew at comparable rates, indicating the triple mutant is capable of inducing factor independent growth. The result of a representative cell proliferation assay with the triple mutant is shown in Figure 1A (data not shown for single mutants). The wild type and triple mutant clones represented in Figure 1 were chosen for further study due to similarity in BCR-ABL expression levels. Growth curve measurements for additional wild type and triple mutant clones (Figure S1) were carried out to confirm that the observed phenotypes were not attributable to random mutational events. Assays of proliferation and viability as determined by trypan blue dye exclusion, performed in the presence and absence of IL-3, yielded similar results, with the triple mutant proliferating and remaining viable at levels comparable to wild type and single mutants in the absence of IL-3 (data not shown). Expression levels of BCR-ABL and a triple mutant clone are shown in Figure 1B.
###end p 9
###begin title 10
The triple mutant of BCR-ABL is capable of inducing growth factor independence.
###end title 10
###begin p 11
32D cell lines matched for BCR-ABL expression were analyzed for their requirement of interleukin-3 (IL-3) for growth. (A) Representative graph of cell proliferation assay on 32D cell lines matched for expression of BCR-ABL grown in the absence of IL-3. (B) Western blot of BCR-ABL (upper panel) and ABL (lower panel) showing relative expression levels of cell lines shown in A.
###end p 11
###begin title 12
Kinase Assays
###end title 12
###begin p 13
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Oda1">[17]</xref>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat1">[22]</xref>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat2">[23]</xref>
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Gaston1">[26]</xref>
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Ilaria1">[19]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Roumiantsev1">[20]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Dai1">[25]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Senechal1">[27]</xref>
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g002">Figure 2</xref>
###xml 862 866 862 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Cortez1">[28]</xref>
###xml 1020 1024 1016 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Ilaria1">[19]</xref>
###xml 1026 1030 1022 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Roumiantsev1">[20]</xref>
###xml 1036 1040 1032 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Dai1">[25]</xref>
###xml 1054 1058 1050 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Senechal1">[27]</xref>
###xml 1414 1418 <span type="species:ncbi:10090">mice</span>
It has previously been shown that individual mutations of the Tyr 177 to Phe, and deletion of the SH2 and Proline domains of BCR-ABL do not abolish the associations between BCR-ABL and its substrates [17], [22], [23], [24], [26], nor do they completely abolish the kinase activity [19], [20], [25], [27]. Kinase assays were performed to determine if the kinase activity of BCR-ABL was impaired in the triple mutant. Results, shown in Figure 2, demonstrate the kinase activity of the BCR-ABL triple mutant is 40-50% lower than that of wild type, similar to that of the BCR-ABL mutant lacking only the SH2 domain. The kinase activity of the single mutants has been reported previously by various groups. Cortez et al. investigated the Y177F and SH2 mutants and found they both were able to transphosphorylate an ABL kinase substrate at similar levels to wild type [28]. Ilaria and Roumianstev both saw a decrease in the kinase activity of a DeltaSH2 mutant compared to wild type BCR-ABL using phospho-tyrosine immunoblots [19], [20]. Dai [25] and Senechal [27] examined the DeltaPro mutation in the p185 and p210 backgrounds, respectively, and also demonstrated that the kinase activity was still present in these mutant forms of BCR-ABL. Since, as reported by these groups, mutation of these domains individually does not affect the interaction of BCR-ABL with its substrates, nor its ability to induce leukemia in mice, we focused our investigation on the triple mutant encompassing each of these component mutants in our studies.
###end p 13
###begin title 14
Kinase activity of triple mutant BCR-ABL is 40-50% that of wild type.
###end title 14
###begin p 15
32D cells normalized for BCR-ABL expression were immunoprecipitated and kinase activity was assayed using a peptide substrate containing the consensus ABL kinase binding site. Assays were performed in triplicate for each cell line: wild type (WT), DeltaSH2 and triple mutant.
###end p 15
###begin title 16
Protein-protein interactions with BCR-ABL wild type and triple mutant
###end title 16
###begin p 17
###xml 268 271 268 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 358 376 358 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g003">Figure 3A, B and C</xref>
###xml 500 509 500 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g003">Figure 3D</xref>
###xml 580 584 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
To further analyze the biochemical properties of cell lines expressing the triple mutant, whole cell lysates from independent clones were analyzed by immunoprecipitation and immunoblotting. These studies demonstrated that the associations between BCR-ABL and GRB2, p62DOK and c-CBL, were strongly reduced, but not completely eliminated in the triple mutant (Figure 3A, B and C). Surprisingly, the amount of CRKL interacting with the triple mutant remained comparable to that of the wild type clones (Figure 3D), which is similar to previous results with the DeltaPro mutant alone [24].
###end p 17
###begin title 18
Interaction of BCR-ABL with various adaptor proteins is reduced, but not eliminated in the triple mutant.
###end title 18
###begin p 19
###xml 224 227 224 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
Lysates from the BCR-ABL expressing 32D cell lines, control line K562 and parental 32D cells were immunoprecipitated (IP) for the indicated proteins and blotted to determine interactions between BCR-ABL and (A) GRB2; (B) p62DOK; (C) CBL; and (D) CRKL. Lower panels show normalization for levels of immunoprecipitated proteins: (A and B) BCR-ABL, (C) CBL and (D) CRKL. In (D), the increased amount of BCR-ABL in the triple mutant lane on the left compared to the outermost lane reflects the correspondingly greater amount of immunoprecipitated CRKL in this lane.
###end p 19
###begin title 20
Tyrosine phosphorylation of BCR-ABL substrates
###end title 20
###begin p 21
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 334 342 334 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4</xref>
###xml 394 403 394 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4A</xref>
###xml 544 545 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 776 785 776 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4B</xref>
###xml 787 788 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 812 821 812 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4C</xref>
###xml 823 824 823 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1225 1228 1225 1228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1230 1239 1230 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4D</xref>
###xml 1241 1242 1241 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1262 1271 1262 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4E</xref>
###xml 1273 1274 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The level of tyrosine phosphorylation of BCR-ABL, c-CBL, CRKL, p62DOK and STAT5 were assessed next. Tyrosine phosphorylation levels from three different experiments were quantitated and normalized for total levels of the specific protein being analyzed. The phosphorylation levels relative to wild type (defined as 100%) are shown in Figure 4 along with representative immunoblots. As shown in Figure 4A, the relative level of BCR-ABL tyrosine phosphorylation is reduced by approximately two-fold in the triple mutant as compared to wild type (p = 0.007), consistent with the reduced kinase activity. Similarly, CBL, which is a component of the BCR-ABL signaling complex, and CRKL, which is directly associated with and phosphorylated by BCR-ABL, are approximately four-fold (Figure 4B; p = 0.003) and two-fold (Figure 4C; p = 0.034) less efficiently tyrosine phosphorylated in the context of the triple mutant as compared to wild type BCR-ABL, consistent with reduced BCR-ABL kinase activity and partial disruption of key docking elements within the triple mutant critical to efficient assembly of the BCR-ABL signaling complex. In contrast, the relative tyrosine phosphorylation levels of the downstream BCR-ABL targets p62DOK (Figure 4D; p = 0.81) and STAT5 (Figure 4E; p = 0.38), are unchanged in the setting of triple mutant BCR-ABL. Wild type BCR-ABL and the triple mutant are equally sensitive to imatinib, as evidenced by complete suppression of tyrosine phosphorylation upon treatment with 10 microM imatinib. In both cases, tyrosine phosphorylation of all examined downstream targets is also abrogated.
###end p 21
###begin title 22
Phosphorylation of various BCR-ABL substrates in wild type and triple mutant BCR-ABL expressing cell lines.
###end title 22
###begin p 23
###xml 386 389 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
Phosphotyrosine levels were determined by immunoprecipitating the indicated proteins from BCR-ABL expressing 32D cell lines and immunoblotting with an anti-phosphotyrosine antibody. The levels of phosphorylation were normalized for the levels of the immunoprecipitated protein, and phosphorylation is reported relative to wild type (right panel). (A) BCR-ABL; (B) CBL; (C) CRKL; (D) p62DOK; (E) STAT5. Treatment with 10uM imatinib inhibited phosphorylation of all substrates examined. Data represents three separate experiments, with a representative blot for each shown in the left panels.
###end p 23
###begin title 24
Activation state of signaling pathways
###end title 24
###begin p 25
###xml 231 239 231 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5</xref>
###xml 272 280 272 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4</xref>
###xml 673 682 673 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5A</xref>
###xml 684 685 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 738 747 738 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4E</xref>
###xml 840 849 840 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5B</xref>
###xml 875 876 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 900 909 888 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5C</xref>
###xml 934 935 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 963 972 939 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5D</xref>
###xml 998 999 962 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The activation state of various signaling proteins activated by BCR-ABL (STAT5, MAPK, MEK and AKT) was analyzed in whole cell lysates from cells expressing wild type BCR-ABL and the triple mutant, using phosphospecific antibodies (Figure 5). As with the data presented in Figure 4, the level of phosphorylation from three different experiments was quantitated and normalized for expression of the specific protein being analyzed. The phosphorylation levels relative to wild type (defined as 100%) are shown. The relative level of STAT5 tyrosine phosphorylation was slightly reduced in the triple mutant as compared to wild type, but did not reach statistical significance (Figure 5A; p = 0.061), consistent with findings described above (Figure 4E). In contrast, statistically significant reductions in the relative levels of phospho-MAPK (Figure 5B; approximatelyfour-fold; p = 0.003), phospho-MEK (Figure 5C; approximatelytwo-fold; p = 0.004), and phospho-AKT (Figure 5D; approximatelyfive-fold; p = 0.001) were evident in the setting of the BCR-ABL triple mutant.
###end p 25
###begin title 26
Activation state of various signaling pathways, in the triple mutant BCR-ABL expressing cells, relative to wild type.
###end title 26
###begin p 27
32D cell lines expressing either wild type or triple mutant BCR-ABL were lysed and the activation state of the indicated signaling pathways was detected by immunoblotting whole cell lysates with phosphospecific antibodies for each pathway. (A) phospho-STAT5; (B) phospho-MAPK; (C) phospho-MEK; (D) phospho-AKT. The levels of phosphorylation were normalized for the whole cell levels of the protein shown in the lower panel of each immunoblot. (A) STAT5; (B) MAPK; (C) MEK; (D) AKT. Phosphorylation levels are reported relative to wild type (upper panels). Data represents three independent experiments with a representative blot shown.
###end p 27
###begin p 28
###xml 341 349 341 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g006">Figure 6</xref>
###xml 399 409 399 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figures 4E</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">5A</xref>
###xml 571 582 571 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g006">Figure 6A,B</xref>
The level of STAT5 phosphorylation was also analyzed in primary bone marrow cells infected with matched retroviral stocks for the triple mutant, wild type BCR-ABL or vector control. GFP positive cells were isolated from each of the infected cell groups and the level of STAT5 phosphorylation measured by flow cytometry and western blotting (Figure 6). Similar to the results seen in the cell lines (Figures 4E and 5A), the levels of phospho-STAT5 in bone marrow infected with the triple mutant is comparable to that seen in wild type relative to the vector only control (Figure 6A,B).
###end p 28
###begin title 29
Analysis of phospho-STAT5 in primary cells.
###end title 29
###begin p 30
GFP positive primary bone marrow transduced with retroviral supernatants from wild type, triple mutant BCR-ABL or vector only was analyzed for the levels of STAT5 phosphorylation by (A) FACS analysis of cells gated for GFP positivity and stained with phospho-STAT5-Alexa 647 antibody or by (B) Western analysis with the indicated antibodies.
###end p 30
###begin title 31
The BCR-ABL triple mutant fails to induce the outgrowth of B-lymphoid cells and myeloid cells
###end title 31
###begin p 32
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 360 369 360 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g007">Figure 7A</xref>
###xml 562 571 562 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g007">Figure 7B</xref>
###xml 631 640 631 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g007">Figure 7C</xref>
The ability of the BCR-ABL triple mutant to transform primary B-lymphoid cells was assessed in Whitlock-Witte cultures. In these assays, cells were plated in serial dilutions, from 1x103 cells per well to 1x105 cells per well. The wells were assessed daily for outgrowth, with wells containing at least 1x106 non-adherent cells scored as positive. As shown in Figure 7A, wild type BCR-ABL induced outgrowth at all but the lowest dilution (yellow line). In contrast the triple mutant was unable to induce the outgrowth of B-lymphoid cells at any dilution plated (Figure 7B), similar to the results seen with the MIG vector control (Figure 7C).
###end p 32
###begin title 33
BCR-ABL triple mutant fails to induce the outgrowth of progenitor B-lymphoid cells and myeloid progenitor cells.
###end title 33
###begin p 34
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 485 486 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Transformation of primary B-lymphoid progenitors was assessed in Whitlock/Witte cultures with bone marrow incubated with retroviral supernatants from (A) wild type; (B) triple mutant; and (C) vector only. Cells are plated in serial dilutions from 1x105 (black line), 3x104 (blue line), 1x104 (red line), 3x103 (green line), 1x103 (yellow line), along with 1x106 non-transduced bone marrow cells. Cultures are scored positive for growth when the number of non-adherent cells exceeded 106 per mL of culture medium. Myeloid transformation potential in the presence (D) or absence (E) of cytokines was measured using colony-forming assays of bone marrow transduced with retroviral supernatants from wild type, triple mutant or vector only. were identical in two separate assays.
###end p 34
###begin p 35
###xml 254 257 254 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-McLaughlin1">[4]</xref>
###xml 496 505 496 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g007">Figure 7D</xref>
###xml 629 638 629 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g007">Figure 7E</xref>
###xml 290 296 <span type="species:ncbi:10090">murine</span>
The triple mutant was also assessed for transformation ability in myeloid colony forming assays. Normal bone marrow requires the addition of cytokines to support colony formation in semisolid media, while expression of BCR-ABL abrogates this requirement [4]. In methylcellulose cultures of murine bone marrow infected with BCR-ABL and supplemented with IL-3, IL-6 and SCF, there was no statistically significant difference between the ability of the triple mutant and wild type to form colonies (Figure 7D). However in the absence of cytokines, the triple mutant yielded only 4% of the colonies formed in the wild type cultures (Figure 7E). To determine whether the colonies growing under the various conditions contained the BCR-ABL construct, individual colonies were analyzed for GFP by PCR. In the presence of growth factors, 80% of colonies from the vector only and triple mutant cultures expressed GFP compared to 100% of wild type colonies. Though only 4 colonies were present in the triple mutant cultures without growth factors, all expressed GFP (data not shown). Thus, the triple mutant appears to have a profound defect in its ability to transform primary cells as measured in these assays.
###end p 35
###begin title 36
###xml 54 58 <span type="species:ncbi:10090">mice</span>
The BCR-ABL triple mutant fails to induce leukemia in mice
###end title 36
###begin p 37
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 371 380 371 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8A</xref>
###xml 833 842 833 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8A</xref>
###xml 957 964 957 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007439-t001">Table 1</xref>
###xml 1064 1082 1064 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8C; b, e, h</xref>
###xml 1138 1156 1138 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8C; a, d, g</xref>
###xml 1279 1297 1279 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8C; c, f, i</xref>
###xml 1862 1871 1862 1871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8B</xref>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 626 631 <span type="species:ncbi:10090">mouse</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 874 878 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
###xml 1401 1405 <span type="species:ncbi:10090">mice</span>
###xml 1546 1550 <span type="species:ncbi:10090">mice</span>
###xml 1600 1604 <span type="species:ncbi:10090">mice</span>
###xml 1762 1767 <span type="species:ncbi:10090">mouse</span>
###xml 1881 1885 <span type="species:ncbi:10090">mice</span>
To assess the ability of the triple mutant to induce a myeloproliferative disease in vivo, lethally irradiated Balb/c mice were transplanted with bone marrow transduced with wild type, triple mutant or empty vector. Assays were carried out using retroviral supernatants of MIG-wild type, the MIG-triple mutant and MIG vector only, matched for GFP expression. As shown in Figure 8A, the triple mutant failed to induce leukemia. Four of 5 mice transplanted with bone marrow infected with the triple mutant vector survived up to 294 days post transplant when they were sacrificed for pathological examination of tissues. A fifth mouse was sacrificed after 118 days for pathological examination to look for evidence of disease. For comparison, mice transplanted with wild type virus had a post-transplant survival of between 20-24 days (Figure 8A). Peripheral blood counts from mice transplanted with the triple mutant and vector only were in the normal range (Table 1). The tissues harvested from the triple mutant mice showed no obvious morphological abnormalities (Figure 8C; b, e, h), and were similar to the vector only control animals (Figure 8C; a, d, g). In contrast the wild type mice exhibited massive expansion of leukemic cells in the liver, spleen and peripheral blood (Figure 8C; c, f, i). Southern blots were performed using genomic DNA from the spleens and bone marrow of the transplanted mice to analyze for integration of viral DNA, using the IRES from the MIG vector as a probe. Proviral integration was only seen in the wild type mice and in the bone marrow of one of the vector only mice (data not shown). As the sensitivity of Southern blot analysis is relatively low, PCR was performed to amplify GFP from RNA isolated from the spleen of each mouse, to ensure that there was expression of the retroviral constructs in each animal. As shown in Figure 8B, all the mice transplanted with the triple mutant expressed the retroviral vector, suggesting the presence of a small population of cells transduced with the retroviral construct was present, but failed to expand.
###end p 37
###begin title 38
###xml 50 54 <span type="species:ncbi:10090">mice</span>
BCR-ABL triple mutant fails to induce leukemia in mice.
###end title 38
###begin p 39
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 235 239 <span type="species:ncbi:10090">Mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
Murine bone marrow transplantation studies were performed, transplanting bone marrow infected with retroviral supernatant from MIG-BCR-ABL-wild type, MIG- BCR-ABL-triple mutant or MIG vector alone, into lethally irradiated recipients. Mice were monitored post transplant for signs of disease onset. (A) Survival curves for the three recipient populations. (B) Green fluorescent protein (GFP, upper panel) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH, lower panel) was amplified by RT-PCR from RNA purified from spleens of triple mutant, wild type or vector only recipients and visualized on agarose gels. (C) H&E stain from the liver (a-c), spleen (d-f) and Wright/Giemsa stain from peripheral blood smear (g-i) of representative mice at harvest; vector only (upper panels), triple mutant (center panels) and wild type (lower panels).
###end p 39
###begin title 40
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Clinical characteristics of mice transplanted with MIG vector, MIG-WT and MIG-triple mutant.
###end title 40
###begin p 41
###xml 35 39 <span type="species:ncbi:10090">mice</span>
See text for details. Pre-moribund mice transplanted with MIG vector, MIG-wild type and MIG-triple were sacrificed for pathological evaluation. Counts of total white blood cells (WBC), lymphocytes (Lym), monocytes (Mon) and granulocytes (Gra) were analyzed from peripheral blood on a VetABC blood analyzer. Livers and spleens were harvested, weighed and analyzed histologically.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
###xml 806 809 806 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 867 871 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat1">[22]</xref>
###xml 873 877 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat2">[23]</xref>
###xml 1047 1051 1047 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler2">[21]</xref>
###xml 1053 1057 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat1">[22]</xref>
###xml 1065 1068 1065 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Bhat2">[23]</xref>
###xml 1241 1245 1241 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Cheng1">[29]</xref>
###xml 1340 1344 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Dinulescu1">[30]</xref>
The BCR-ABL protein is known to associate with and activate numerous cellular signaling proteins. The emerging view is that BCR-ABL assembles a multi-protein complex whose signaling output leads to cellular transformation. Deciphering the contribution to transformation of individual domains of BCR-ABL or signaling proteins has been problematic as many proteins can interact both directly and indirectly with BCR-ABL. For example, deletion of a proline-rich motif in the C-terminus of BCR-ABL abolishes direct binding of BCR-ABL to the N-terminal SH3 domain of CRKL; however, CRKL remains tyrosine phosphorylated and associated with BCR-ABL in cells expressing this deletion mutant [24]. This is likely the result of interactions between CRKL and other adaptor or signaling molecules, such as c-CBL or p62DOK which have been shown to link CRKL indirectly to BCR-ABL [22], [23]. In addition, an individual domain or binding site can mediate binding to more than one protein. For example, the SH2 domain mediates an association of BCR-ABL with CBL [21], [22] and p62DOK[23]. Even the use of animals that lack specific signaling proteins has not been particularly revealing. In some cases, such as GRB2, the null phenotype is embryonic lethal [29]. In others, such as c-CBL null animals, no defect in BCR-ABL transformation has been observed [30]. This result could be interpreted as a lack of necessity of the specific protein for BCR-ABL function or compensation for the deleted gene by other proteins.
###end p 43
###begin p 44
###xml 677 684 665 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 830 834 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Million1">[16]</xref>
###xml 836 840 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Roumiantsev1">[20]</xref>
###xml 906 913 894 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCR-ABL</sup>
###xml 1404 1408 1392 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Dai1">[25]</xref>
###xml 583 589 <span type="species:ncbi:10090">murine</span>
###xml 748 752 <span type="species:ncbi:10090">mice</span>
###xml 1272 1276 <span type="species:ncbi:10090">mice</span>
###xml 1399 1403 <span type="species:ncbi:10090">mice</span>
To investigate the necessity of various signaling proteins for BCR-ABL, we sought to identify a BCR-ABL mutant that remained kinase active, yet lacked transformation capacity. This was accomplished by the construction of a triple mutant including the Y177F substitution in BCR and deletions of the SH2 and the C-terminal proline-rich domains of ABL. In isolation the Y177F, DeltaSH2 and DeltaPro single mutants of BCR-ABL are capable of rendering myeloid cells IL-3 independent for growth, but they are much less potent than wild type BCR-ABL for transformation of fibroblasts. In a murine bone marrow transplantation model both the Y177F and DeltaSH2 mutants induced leukemia in vivo, however in contrast to the myeloid phenotype of the wild type mice the phenotype of these single mutants was lymphoid and latency was increased [16], [20]. The C-terminal proline-rich domain has been examined in the p185BCR-ABL background as a single mutation and in combination with deletion of the ABL SH3 domain. Mutants expressing a deletion of the proline-rich domain alone and in combination with the SH3 domain were also capable of transforming hematopoietic cells to factor independent growth. The single mutations induced a leukemia similar to wild type when transplanted into mice, however the double mutant induced an undetermined disease with recipients surviving twice as long as wild type recipient mice [25].
###end p 44
###begin p 45
###xml 146 154 138 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g001">Figure 1</xref>
###xml 518 526 510 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g007">Figure 7</xref>
###xml 630 637 622 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 691 699 683 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8</xref>
###xml 852 859 844 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 861 869 853 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 1036 1044 1024 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g002">Figure 2</xref>
###xml 1141 1145 1125 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Oda1">[17]</xref>
###xml 1147 1151 1131 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Ilaria1">[19]</xref>
###xml 1153 1157 1137 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Roumiantsev1">[20]</xref>
Using a triple mutant of BCR-ABL (Y177F, DeltaSH2, and DeltaPro), we show that this mutant still confers growth factor independence to 32D cells (Figure 1), but exhibits a profound defect in the transformation of primary hematopoietic cells. To this end, we show that in Whitlock-Witte B-cell transformation assays the ability of the triple mutant to induce outgrowth is completely abrogated. Furthermore, the ability to form myeloid colonies in the absence of cytokines is severely compromised relative to wild type (Figure 7). Consistent with these observations, the triple mutant was found to be incapable of inducing leukemia in vivo in a bone marrow transduction/transplantation model (Figure 8). Thus, the mutant described here represents the first report of a BCR-ABL mutant retaining kinase activity that is completely transformation deficient in vivo. In vitro kinase assays revealed that the kinase activity of the triple mutant, although reduced compared to wild type, is equal to the activity of the DeltaSH2 single mutant (Figure 2). As the DeltaSH2 mutant retains transformation competency in both cell lines and primary cells [17], [19], [20], this strongly suggests that the reduced kinase activity is not causing the transformation defect.
###end p 45
###begin p 46
###xml 222 230 222 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Onishi1">[31]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Cortez1">[28]</xref>
###xml 798 801 798 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 838 846 838 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g004">Figure 4</xref>
###xml 931 934 931 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1085 1088 1085 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1146 1149 1146 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1248 1252 1248 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Shah1">[32]</xref>
###xml 1592 1596 1592 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Salgia1">[33]</xref>
###xml 1747 1751 1747 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Senechal2">[34]</xref>
###xml 1891 1895 1891 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler2">[21]</xref>
###xml 2099 2103 2099 2103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Senechal1">[27]</xref>
###xml 2386 2390 2382 2386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
###xml 2750 2758 2746 2754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g003">Figure 3</xref>
Examination of the canonical BCR-ABL signaling pathways in 32D cells showed that only STAT5 activation was maintained at wild type levels, suggesting that activation of STAT5 may be sufficient to induce IL-3 independence (Figure 5). This is consistent with a report by Onishi and colleagues, that a constitutively active STAT5 mutant is capable of inducing IL-3 independent growth [31]. In contrast, the significantly reduced activity of the MAP kinase and PI3-kinase/AKT pathways suggest that they are not required for BCR-ABL to induce growth factor independence in the triple mutant cell lines. This is consistent with the findings of Cortez et al, that RAS activation alone is not sufficient for transformation by BCR-ABL [28]. In addition to STAT5 we found that tyrosine phosphorylation of p62DOK is maintained in the triple mutant (Figure 4), in contrast to CBL and CRKL tyrosine phosphorylation. Thus it is possible that p62DOK phosphorylation in addition to STAT5 is required for factor-independent growth. Many groups have attempted to determine the role of phosphorylated p62DOK in cellular signaling and suggest that phosphorylated p62DOK plays a role in the negative regulation of growth factor stimulated pathways and/or RAS signaling [32]. Our data suggest that CBL and CRKL phosphorylation are primarily required for modulation of cellular functions other than factor independent proliferation and survival. For example, signaling through CRKL could affect adhesion and migration via interactions with paxillin, CAS and CBL and by forming complexes with focal adhesion kinases [33]. It has also been suggested that CRKL may play a role in signaling via its interactions with integrins, B- and T-cell receptors and various cytokines [34]. CRKL and CBL have been shown to interact in a multi-protein complex along with PI3-kinase when phosphorylated in BCR-ABL expressing cells [21]. Additionally, phosphorylated CRKL can transform fibroblasts through association with SOS and C3G, thereby activating the RAS pathway, analogous to the role of GRB2 in the activation of the same pathway [27]. The pattern of tyrosine phosphorylation in the BCR-ABL triple mutant points out the complexity of BCR-ABL signaling. We have shown that CRKL co-immunoprecipitates with the DeltaPro mutant of BCR-ABL in cellular lysates, although this mutant is not capable of directly binding CRKL [24], and suggested that this interaction may be mediated by an association between CRKL and CBL, which in turn binds to the ABL SH2 domain in a tyrosine dependent manner. However, in the triple mutant, CRKL tyrosine phosphorylation and the association of CRKL and BCR-ABL are maintained, although the interaction between BCR-ABL and CBL is significantly reduced (Figure 3). As we know that there is no direct interaction between BCR-ABL and CRKL in the DeltaPro mutant, this suggests that an unidentified protein(s) mediates the indirect interaction between CRKL and BCR-ABL.
###end p 46
###begin p 47
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 223 231 223 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g005">Figure 5</xref>
###xml 595 599 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Goga1">[15]</xref>
###xml 744 751 744 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Skorski1">[35]</xref>
Despite activation of STAT5, the BCR-ABL triple mutant is not able to induce leukemia in vivo. As noted, several signaling pathways are significantly impaired in this mutant, including the MAPK and PI3-kinase/AKT pathways (Figure 5). The fact that the respective single mutants are leukemogenic suggests that the combination of all three mutations abolishes leukemogenicity by overcoming the redundancy of the system. For example, the BCR-ABL Y177F mutant is deficient in GRB2 binding, but still activates RAS in 32D and BaF3 cells, likely via SH2 domain dependent interaction with GRB2 and SHC [15]. The fact that RAS activation via the SH2 domain is preserved in the Y177F mutant could explain why this mutant still maintains leukemogenicity in vivo. In addition, the SH2 domain of BCR-ABL has been shown to be required for activation of AKT through its association with the p85 subunit of PI3-kinase [35]. The combined impairment of PI3-kinase and RAS activation may explain the triple mutant's inability to transform primary hematopoietic progenitor cells.
###end p 47
###begin p 48
###xml 178 186 178 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007439.s002">Table S1</xref>
###xml 404 413 404 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g008">Figure 8B</xref>
###xml 1228 1236 1228 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007439-g006">Figure 6</xref>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 1517 1521 <span type="species:ncbi:10090">mice</span>
It is not entirely clear which precise functional defect is responsible for the loss of leukemogenic potential. Bone marrow containing similar percentages of GFP positive cells (Table S1) of vector control, wild type or triple mutant were used for transplantation. Proviral integration in hematopoietic tissues from mice transplanted with bone marrow infected with the triple mutant was detected by PCR (Figure 8B), but not Southern blotting, indicating that only a small fraction of hematopoietic cells contained the triple mutant construct. Our results suggest that hematopoietic cells transduced with the triple mutant are at a selective disadvantage compared to cells transduced with wild type BCR-ABL or empty vector, as their proportion was reduced after engraftment. Further experiments will be required to determine whether this reflects failure of the cells to engraft or failure to expand after engraftment. The data from the B-cell and myeloid colony assays are clearly much more compatible with the second possibility. The data from the primary hematopoietic cells also support this assertion. Given the evidence demonstrating expression of BCR-ABL and of comparable levels of downstream signaling in primary cells (Figure 6), the identical nature of the vector backbone in all three constructs used and the fact that cell lines with high expression of the triple mutant were easily derived, low expression of the triple mutant does not appear to be a plausible explanation for the lack of disease in the mice transduced with the triple mutant bone marrow.
###end p 48
###begin p 49
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Kardinal1">[36]</xref>
In summary, we show that mutation of BCR-ABL tyrosine 177 to phenylalanine in combination with deletion of the SH2 and proline rich domains abolishes the capacity of BCR-ABL to transform primary hematopoietic progenitor cells, but remains capable of inducing factor-independent growth in cell lines. This implies that a combination of small molecules that simultaneously block Y177 [36], the protein binding SH2 domain and the proline rich region could suppress BCR-ABL induced leukemia despite maintenance of kinase activity.
###end p 49
###begin title 50
Materials and Methods
###end title 50
###begin title 51
###xml 23 27 23 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p210</sup>
Construction of BCR-ABLp210 mutants
###end title 51
###begin p 52
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Pendergast1">[13]</xref>
###xml 130 134 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Oda1">[17]</xref>
###xml 205 209 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Heaney1">[24]</xref>
###xml 1084 1088 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Muller1">[37]</xref>
###xml 1366 1369 1306 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Zhang1">[2]</xref>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 1033 1036 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1515 1521 <span type="species:ncbi:10090">murine</span>
Constructs containing the point mutation of tyrosine 177 to phenylalanine (Y177F) [13], deletion of the ABL SH2 domain (DeltaSH2) [17], and deletion of the proline-rich region of the C terminus (DeltaPro) [24], have been described previously. A "triple mutant" construct containing all three changes was created from wild-type BCR-ABL by a series of standard subcloning steps in a modified pGEM5z vector (Promega, Madison, WI, USA). We recognize that since BCR-ABL is a fusion protein that is not naturally occurring, the term "wild type" is technically incorrect. However, cumbersome terminology such as "BCR-ABL with no mutations in the coding sequences of BCR and ABL" would be required to accurately describe the starting clone. For this reason, we have chosen to use the term wild type to describe the fusion protein that is observed in patients with CML. The wild type, Y177F, DeltaSH2, DeltaPro and triple mutant forms of BCR-ABL were excised from the modified pGEM5z vector as EcoR1 cassettes and subcloned into the pSRalpha-MSV-tk-neo retroviral expression vector (pSRalpha) [37], yielding plasmids pSRalpha-p210-wild type (WT), pSRalpha-p210-Y177F (Y177F), pSRalpha-p210-DeltaSH2 (DeltaSH2), pSRalpha-p210-DeltaPro (DeltaPro) and pSRalpha-triple mutant (triple) for expression in 32Dcl3 cells. Constructs were also subcloned into the MSCV-IRES-GFP (MIGR1) [2], yielding plasmids MIG-p210 wild type (WT) and MIG-triple mutant (triple) for use in B-cell lymphoid outgrowth assays, colony forming assays and murine bone marrow transplantation experiments.
###end p 52
###begin title 53
Cells and cell culture
###end title 53
###begin p 54
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Greenberger1">[38]</xref>
###xml 337 341 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Pear1">[39]</xref>
###xml 1002 1006 994 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Lozzio1">[40]</xref>
###xml 412 418 <span type="species:ncbi:9913">bovine</span>
###xml 480 486 <span type="species:ncbi:10090">murine</span>
The 32Dcl3 cell line (herein referred to as 32D cells) was obtained from Joel Greenberger, University of Massachusetts Medical Center, Worcester, MA [38]. 32D cell lines expressing wild type, Y177F, DeltaSH2, DeltaPro and the triple were generated by electroporation or by infection with retroviral supernatant generated from 293T cells [39]. Mass cultures were expanded in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 15% WEHI-3B conditioned media as a source of murine interleukin-3 (IL-3). Individual clones were isolated by plating cells in 0.25% soft agar (Seakem, FMC Bioproducts, USA) in complete media containing 15% WEHI-3B conditioned media. Individual colonies were picked after 10-14 days and expanded in RPMI-1640 supplemented with 10% FBS and 15% WEHI-3B conditioned media. With IL-3 in the media, selection for growth factor independence was avoided. Individual clones were analyzed for BCR-ABL expression by immunoblot analysis. K562 cells, a BCR-ABL positive cell line [40], were cultured in RPMI-1640 supplemented with 10% FBS. Imatinib, kindly provided by E. Buchdunger (Novartis, Basel, Switzerland) was prepared freshly as a 10 mM stock solution in sterile phosphate-buffered saline (PBS) and diluted in RPMI 1640 medium immediately prior to use.
###end p 54
###begin title 55
Cell proliferation and viability assays
###end title 55
###begin p 56
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Mosmann1">[41]</xref>
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 582 583 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Factor independent growth was assessed with a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) (Promega, Madison, WI, USA) assays as described [41]. Briefly, 1x104 cells were plated in quadruplicate wells of four separate 96 well plates, with and without IL-3. MTS was added to one plate, which was incubated at 37degreesC for 4 hours, followed by measurement of the optical density (OD) at 490 nm. This was repeated at 24 hour intervals with the remaining three plates. For cell viability assays, 2x106 cells were cultured in T25 flasks, with and without IL-3. Viable cells that excluded trypan blue were counted daily for 7 days.
###end p 56
###begin title 57
Kinase assays
###end title 57
###begin p 58
###xml 385 389 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Brasher1">[42]</xref>
###xml 391 395 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-OHare1">[43]</xref>
###xml 762 763 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 765 766 758 759 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 779 780 772 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 908 910 891 893 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1093 1094 1076 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Immunoprecipitated wild type, DeltaSH2, and triple mutant BCR-ABL proteins from the 32D cell lines were used to measure the relative kinase activity of the proteins. Kinase activity was assayed using a synthetic NH2-terminal biotin linked peptide substrate containing the consensus binding sequence for the ABL kinase (biotin-EAIYAAPFAKKK-amide; New England Peptide, Gardner, MA, USA) [42], [43]. Briefly, 32D cell lysates normalized for BCR-ABL expression were immunoprecipitated using the ABL antibody (K12, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) followed by incubation with protein-A-sepharose. Immunoprecipitates were washed extensively in kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM DTT, 0.1 mM sodium orthovanadate [Na3VO4], 10 mM MgCl2) and resuspended in the same. Kinase assays were incubated at 30degreesC for 10 minutes in kinase buffer plus 50 uM ATP, [gamma32P]ATP at 5000-5000 cpm/pmol and 2 uM peptide substrate. Assays were terminated with guanidine hydrochloride. A portion of the assay was spotted onto streptavidin coated membranes (SAM2(R), Promega, Madison, WI), washed and dried as recommended by the manufacturer. Phosphate incorporation was detected by liquid scintillation counting. Assays were performed in triplicate for each BCR-ABL protein, with and without imatinib in the assay to control for kinase activity due to other kinases aside from BCR-ABL that might be present in the immunoprecipitates. Background binding was corrected using reactions containing no peptide. Counts were averaged in each assay, corrected for background counts and for BCR-ABL expression, as determined by Western blotting. Three replicate assays were performed and the activity relative to p210 wt was calculated.
###end p 58
###begin title 59
Immunoprecipitations and immunoblotting
###end title 59
###begin p 60
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 152 153 152 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1526 1529 1520 1523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
###xml 1885 1888 1879 1882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DOK</sup>
Cells were lysed in NP40 lysis buffer (20 mM Tris, pH 8.0, 1 mM EDTA, 150 mM NaCl, 1% NP40, 10% glycerol, also containing 10 ug/mL aprotinin, 1 mM Na3VO4 and 1 mM phenylmethylsulfonyl fluoride). Equal amounts of whole cell lysate were run on SDS-PAGE gels and transferred to PVDF membranes (Immobilon-P, Millipore, Temecula, CA, USA) for 4 hours at 0.55 amps in 25 mM Tris, 192.5 mM glycine and 20% methanol. Non-specific binding sites were blocked with either 2.5% gelatin (for anti-phosphotyrosine blots) or 5% non-fat milk in TBS-T (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween20) for 1 h at 25degreesC. The blots were incubated at room temperature with anti-phosphotyrosine antibodies (4G10), from Millipore, or one of the following antibodies from Cell Signaling (Beverly, MA, USA): phospho-AKT (S473), phospho-MAPK (T202/Y204), phospho-STAT5 (Y694) or phospho-MEK (S217/221). Blots were stripped and reprobed with antibodies recognizing AKT, MAPK, STAT5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MEK (Cell Signaling), respectively. Antibody reactions were detected by enhanced chemiluminescence (Pierce, Rockford, IL, USA) and quantitated using the Lumi Analyst software (Boehringer Mannheim, Roche Diagnostics, Indianapolis, IN, USA). For immunoprecipitation studies, equal amounts of lysate were incubated with antibody followed by incubation with either protein A- or G-sepharose. Antibodies used for immunoprecipitations were: c-CBL (C-15), c-ABL (K12), CRKL (C-20) and STAT5 (C-17) from Santa Cruz and p62DOK from Covance Research Products (Grand Rapids, MI, USA). Immunoprecipitated lysates were separated on SDS-PAGE gels and transferred to PVDF membranes as above and the membranes were incubated with the following antibodies: anti-phosphotyrosine (4G10), anti-GRB2 (3F2), Millipore Corporation, anti-ABL (2411), anti-CRKL (C20), anti-STAT5 (C-17) and anti-p62DOK (A3) from Santa Cruz and anti-CBL from BD Biosciences (San Diego, CA, USA).
###end p 60
###begin title 61
Generation of retrovirus
###end title 61
###begin p 62
###xml 13 17 13 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Pear1">[39]</xref>
###xml 506 510 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Kotani1">[44]</xref>
Bosc23 cells [39] were maintained in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% FBS, 1 U/mL penicillin, and 1 microg/mL streptomycin. For production of retrovirus, Bosc23 cells were transiently transfected with MIG-WT, MIG-Triple or control MIG vector retrovirus, using Fugene (Roche). The viral supernatants were harvested after 48 hours post-transfection. For titration of retroviral supernatants, 100,000 NIH3T3 cells were infected in 35 mm plates with graded amounts of supernatant [44]. After 48 hours the cells were analyzed for GFP expression by FACS using a BD FACSAriatrade mark (BD Biosciences). Volumes of supernatant containing equal amounts of infectious particles were used to infect primary hematopoietic cells.
###end p 62
###begin title 63
Analysis of phospho-STAT5 in primary cells
###end title 63
###begin p 64
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 110 111 110 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 671 675 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler3">[45]</xref>
###xml 1020 1021 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 245 251 <span type="species:ncbi:10090">murine</span>
###xml 267 273 <span type="species:ncbi:10090">murine</span>
###xml 292 298 <span type="species:ncbi:10090">murine</span>
###xml 1264 1269 <span type="species:ncbi:10090">mouse</span>
Bone marrow was harvested from non 5-fluorouracil treated Balb/c mice, erythrocytes were lysed with HN4Cl/KHCO3 solution and the cells were incubated overnight at 37degreesC in DMEM supplemented with 10% FBS, 10% WEHI conditioned media, 6 ng/mL murine IL-3, 10 ng/mL murine IL-6 and 50 ng/mL murine SCF (PeproTech, Inc., Rocky Hill, NJ). The following day fresh media, plus 1 mM HEPES, 2 ug/mL polybrene (American BioAnalytical, Natick, MA) and matched retroviral stock for the triple mutant, wild type or vector control was added, and cells were subjected to two rounds of transduction and co-sedimentation 24 hours apart, separated by incubation overnight at 37degreesC[45]. After the second overnight incubation, GFP positive cells were sorted and collected with a BD FACSAriatrade mark (BD Biosciences, San Jose, CA) followed again by incubation overnight in DMEM supplemented with 10% FBS, IL-3, IL-6 and SCF. Cells were washed twice and starved for 4 hours in DMEM without serum or cytokines. After starvation 5x105 cells were fixed with BDtrade mark Cytofix buffer (10 minutes on ice), permeabilized with BDtrade mark Phosflow Perm Buffer III (30 minutes on ice), washed with BD Pharmingentrade mark Stain Buffer+FBS and stained with the Alexa Fluor(R) 647 mouse anti-Stat5 (pY694) antibody (30 minutes at room temperature, in the dark), followed by analysis on a BD FACSAriatrade mark. Remaining cells were lysed for western analysis of pSTAT5 (Y694) (Cell Signaling) and BCR-ABL (c-ABL, Santa Cruz), stripped and re-probed for STAT5 (Santa Cruz).
###end p 64
###begin title 65
B-lymphoid transformation
###end title 65
###begin p 66
###xml 135 138 135 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-McLaughlin1">[4]</xref>
###xml 171 172 171 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 490 498 490 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 667 671 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Roumiantsev1">[20]</xref>
###xml 673 677 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Million2">[46]</xref>
###xml 738 739 730 731 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 745 746 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 752 753 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 759 760 751 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 769 770 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 796 797 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1069 1070 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
To analyze the transformation of primary bone marrow B-lymphoid progenitors, bone marrow from non 5-fluorouracil treated mice was used [4]. Erythrocytes were lysed with HN4Cl/KHCO3solution and the cells were subjected to a single round of transduction and co-sedimentation with matched retroviral stock for the triple mutant, wild type and vector control in DMEM supplemented with 10% FBS. Cells were incubated overnight in the presence of viral supernatant. The cells were then plated for in vitro growth in Whitlock/Witte cultures in RPMI 1640 supplemented with 5% FBS, 200 microM L-glutamine, 50 microM 2-mercaptonoethanol and penicillin/streptomycin as described [20], [46]. Cells were plated in triplicate in serial dilutions at 1x105, 3x104, 1x104, 3x103 and 1x103 cells/mL, along with 1x106 non-transduced bone marrow cells. Cells were cultured for three weeks and fed twice weekly by the removal of 0.5 mL of supernatant and addition of 0.5 mL of fresh media. Cultures were scored as positive for transformation when the number of non-adherent cells exceeded 106 per mL of culture medium.
###end p 66
###begin title 67
Myeloid Colony Forming Assays
###end title 67
###begin p 68
###xml 396 400 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Sattler3">[45]</xref>
###xml 668 672 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Kotani1">[44]</xref>
###xml 836 837 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1018 1019 994 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 290 296 <span type="species:ncbi:10090">murine</span>
###xml 312 318 <span type="species:ncbi:10090">murine</span>
###xml 337 343 <span type="species:ncbi:10090">murine</span>
For myeloid progenitor colony formation bone marrow was harvested from 6-10 week old female Balb/c mice. Bone marrow was subjected to 24 hours prestimulation at 37degreesC in IMDM (Invitrogen, Carlsbad, CA, USA) supplemented with 5% heat-inactivated FBS, 5% WEHI conditioned media, 6 ng/mL murine IL-3, 10 ng/mL murine IL-6 and 50 ng/mL murine SCF (Stem Cell Technologies, Vancouver, BC, Canada) [45]. After 24 hours of prestimulation, equal numbers of cells were transferred to 6-well plates and exposed to matched viral supernatants in the presence of 2 ug/mL polybrene in the same media as above. Cells were then co-sedimented at 30degreesC for 90 mins at 2500 rpm [44] and returned to the 37degreesC incubator overnight. After overnight incubation, cells were washed twice in IMDM to remove cytokines and plated in duplicate at 1x105 cells in Methocult M3234 without cytokines or erythropoietin or in Methocult M3534 containing IL-3, IL-6 and SCF (Stem Cell Technologies). Cells were incubated at 37degreesC, 5% CO2 for 7 days after which the number of colonies were counted and are reported as a percentage of the number of wild type colonies formed. Genomic DNA was isolated from colonies using the Qiagen (Valencia, CA, USA) micro DNA kit and used in PCR as described below.
###end p 68
###begin title 69
Bone marrow transduction/transplantation
###end title 69
###begin p 70
###xml 90 93 90 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Zhang1">[2]</xref>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 780 784 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Kotani1">[44]</xref>
###xml 884 885 876 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
###xml 1214 1218 <span type="species:ncbi:10090">Mice</span>
Murine bone marrow transduction and transplantation was performed as previously described [2]. Briefly, bone marrow cells were isolated from the tibias and femurs of 6-8 week old male Balb/c donor mice 4-5 days after intravenous treatment with 300 mg/kg of 5-fluorouracil (Sigma-Aldrich, St. Louis, MO, USA). Bone marrow cells (2x106 cells) were infected with either MIG-WT, MIG-triple mutant-BCR-ABL or control MIG retroviral supernatant matched by titering in NIH-3T3 cells as described above, in DMEM (final concentration of viral supernatant of 35%), containing 1 U/mL penicillin, 1 microg/mL streptomycin, 2 mM L-glutamine, 15% FBS, 15% WEHI, 7 ng/mL interleukin-3, 12 ng/mL interleukin-6, 56 ng/mL stem cell factor, and 3 microg/mL polybrene, by two rounds of spinoculation [44]. Following infection, the cells were washed extensively in phosphate buffered saline (PBS) and 4x105 cells were injected into the retro-orbital vein of recipient mice that had been exposed to two doses of 450 rad whole-body irradiation in a cesium irradiator administered 4 hours apart. After transplant, recipients were housed in microisolator cages supplied with water supplemented with antibiotics (Augmentin, OHSU pharmacy). Mice were monitored daily post transplant to look for signs of disease onset. White blood counts (WBC) and three-part differential blood counts were analyzed weekly using a Vet ABC blood analyzer (Heska Inc., Fort Collins, CO, USA).
###end p 70
###begin title 71
PCR amplification of GFP
###end title 71
###begin p 72
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Zhang1">[2]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007439-Kang1">[47]</xref>
Genomic DNA was isolated from myeloid colonies as described above. RNA was isolated from frozen tissue sections of spleens using the RNeasy isolation kit (Qiagen). cDNA was amplified using the Superscript III kit (Invitrogen) and used in PCR to amplify GFP from individual animals as described by Zhang, et al [2]. The GAPDH gene was amplified as a housekeeping control gene as described [47]Results were visualized on agarose gels.
###end p 72
###begin title 73
Southern Blot
###end title 73
###begin p 74
Proviral integration was assessed by Southern blotting. Ten ug of genomic DNA from frozen spleen sections and bone marrow isolated at harvest was digested with EcoR1 and Sal1, run out on 0.8% agarose gel, transferred to Hybond-N+ (GE Healthcare, Piscataway, NJ, USA) and hybridized with a radioactive probe from the IRES gene in MIG-R1. Results were visualized on a Typhoon Imager (GE Healthcare).
###end p 74
###begin title 75
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Pathological examination of diseased mice
###end title 75
###begin p 76
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
For survival analysis, mice were monitored with weekly blood counts using a Vet ABC blood analyzer (Heska Inc.). Animals were sacrificed by CO2 asphyxiation when the white blood cell count exceeded 200/nl, if there was greater than 20% loss of body weight, or if they appeared moribund (IACUC guidelines, Oregon Health & Science University). For pathological analysis tissues were harvested, weighed and analyzed histologically, when the mice were sacrificed or when spontaneous death occurred. Paraffin-embedded thin sections of liver and spleen were stained with hematoxylin and eosin (H&E). Peripheral blood smears were stained with Wright/Giemsa stain. White blood counts (WBC) and three-part differential blood counts were analyzed from peripheral blood using the Vet ABC blood analyzer.
###end p 76
###begin title 77
Ethics Statement
###end title 77
###begin p 78
###xml 4 8 <span type="species:ncbi:10090">mice</span>
All mice used in these experiments were housed and cared for in the OHSU Animal Care Facility under the supervision of the facility's veterinary staff. OHSU is an AAALAC accredited institution, meeting or exceeding all standards for animal care and use. This study has been reviewed and approved by the OHSU's Institutional Animal Care and Use Committee (IACUC). All procedures, such as injections and test bleeds, were performed by experienced personnel according to guidelines established by the IACUC, designed to ensure minimal discomfort and distress of the animals.
###end p 78
###begin title 79
Supporting Information
###end title 79
###begin p 80
Growth curves of the triple mutant and BCR-ABL clones. Independent clones of 32D cells expressing either BCR-ABL wild type or triple mutant were isolated from soft agar cultures and their ability to grow in the absence of IL-3 was evaluated in cell proliferation assays. A representative cell proliferation assay with two wild type and four triple mutant clones is shown.
###end p 80
###begin p 81
(0.30 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
Relative percentage of GFP positive cells in bone marrow used for transplantation. Flow cytometric analysis of the percentage of GFP positive bone marrow cells post infection with the indicated retroviral supernatants used in the bone marrow transplantation/transduction experiments.
###end p 83
###begin p 84
(0.03 MB RTF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 20 24 <span type="species:ncbi:23211">Pear</span>
We thank Dr. Warren Pear and Dr. Ruibao Ren for the MIG vector and assistance with the bone marrow transduction/transplantation, The OHSU Flow Cytometry Core Facility for assistance with the FACS analysis and Chris Koontz for editorial assistance with the manuscript.
###end p 86
###begin title 87
References
###end title 87
###begin article-title 88
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
###end article-title 88
###begin article-title 89
###xml 152 156 <span type="species:ncbi:10090">mice</span>
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
###end article-title 89
###begin article-title 90
###xml 32 35 <span type="species:ncbi:10116">Rat</span>
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
###end article-title 90
###begin article-title 91
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
###end article-title 91
###begin article-title 92
Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
###end article-title 92
###begin article-title 93
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
###end article-title 93
###begin article-title 94
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
###end article-title 94
###begin article-title 95
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
###end article-title 95
###begin article-title 96
###xml 78 83 <span type="species:ncbi:9606">human</span>
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
###end article-title 96
###begin article-title 97
The function of BCR/ABL and related proto-oncogenes.
###end article-title 97
###begin article-title 98
Signal transduction by wild-type and leukemogenic Abl proteins.
###end article-title 98
###begin article-title 99
Signal transduction pathways involved in BCR-ABL transformation.
###end article-title 99
###begin article-title 100
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
###end article-title 100
###begin article-title 101
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
###end article-title 101
###begin article-title 102
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.
###end article-title 102
###begin article-title 103
###xml 96 100 <span type="species:ncbi:10090">mice</span>
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
###end article-title 103
###begin article-title 104
###xml 92 98 <span type="species:ncbi:10090">murine</span>
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.
###end article-title 104
###begin article-title 105
###xml 119 124 <span type="species:ncbi:9606">human</span>
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
###end article-title 105
###begin article-title 106
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
###end article-title 106
###begin article-title 107
###xml 117 121 <span type="species:ncbi:10090">mice</span>
The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
###end article-title 107
###begin article-title 108
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
###end article-title 108
###begin article-title 109
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
###end article-title 109
###begin article-title 110
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
###end article-title 110
###begin article-title 111
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
###end article-title 111
###begin article-title 112
Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis.
###end article-title 112
###begin article-title 113
Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl.
###end article-title 113
###begin article-title 114
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
###end article-title 114
###begin article-title 115
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
###end article-title 115
###begin article-title 116
Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation.
###end article-title 116
###begin article-title 117
###xml 59 63 <span type="species:ncbi:10090">mice</span>
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
###end article-title 117
###begin article-title 118
Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation.
###end article-title 118
###begin article-title 119
A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway.
###end article-title 119
###begin article-title 120
###xml 21 26 <span type="species:ncbi:9606">human</span>
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.
###end article-title 120
###begin article-title 121
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.
###end article-title 121
###begin article-title 122
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
###end article-title 122
###begin article-title 123
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.
###end article-title 123
###begin article-title 124
###xml 120 125 <span type="species:ncbi:9606">human</span>
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
###end article-title 124
###begin article-title 125
Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.
###end article-title 125
###begin article-title 126
Production of high-titer helper-free retroviruses by transient transfection.
###end article-title 126
###begin article-title 127
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.
###end article-title 127
###begin article-title 128
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
###end article-title 128
###begin article-title 129
c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines.
###end article-title 129
###begin article-title 130
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
###end article-title 130
###begin article-title 131
Improved methods of retroviral vector transduction and production for gene therapy.
###end article-title 131
###begin article-title 132
Critical role for Gab2 in transformation by BCR/ABL.
###end article-title 132
###begin article-title 133
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
###end article-title 133
###begin article-title 134
###xml 137 142 <span type="species:ncbi:9606">human</span>
The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells.
###end article-title 134
###begin p 135
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
###xml 140 147 <span type="species:ncbi:9606">patient</span>
Competing Interests: Novartis and Bristol-Myers Squibb. OHSU has clinical trial contracts with Novartis and Bristol-Myers-Squibb to pay for patient costs, nurse and data manager salaries, and institutional overhead. Dr. Druker does not derive salary, nor does his lab receive funds from these contracts. Dr. Deininger is on the Novartis advisory board.
###end p 135
###begin p 136
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by funding from the Howard Hughes Medical Institute, and grants from the National Cancer Institute (RO1 CA65823) and The Leukemia and Lymphoma Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 136

